Anne Covey, MD, discusses options for patients with hepatocellular carcinoma (HCC) who cannot undergo resection or transplant.
Anne Covey, MD, interventional radiologist, Memorial Sloan Kettering Cancer Center, discusses options for patients with hepatocellular carcinoma (HCC) who cannot undergo resection or transplant. Covey says this group of patients is around 80% of those diagnosed with HCC, and the most common form of therapy is locoregional treatment, or therapy targeted to the liver.
Covey says some beneficial locoregional therapies offered to patients with HCC are bland embolization, chemoembolization, radioembolization, embolization with drug-eluding beads, and ablation.
Experts Will Explore Targetable Resistance Approaches During Lung Cancer Conference
May 16th 2025For patients with EGFR-mutated NSCLC, treatment options in the frontline include osimertinib monotherapy, amivantamab with lazertinib, and osimertinib combined with platinum-doublet chemotherapy.
Read More